期刊文献+

标准化^131I治疗与ATD治疗Grave’s甲亢疗效比较 被引量:5

在线阅读 下载PDF
导出
摘要 目的比较标准化^131I治疗与抗甲状腺药物(antithyroid drugs,ATD)治疗Grave’s甲亢的疗效;比较标准化^131I治疗后不同时间段的疗效;比较标准化^131I治疗对老年人与中青年人Grave’s甲亢的疗效。方法标准化^131I治疗组:停用影响甲状腺摄取^131I的食物如海带、紫菜、海鱼等和药物如他巴唑、丙基硫氧嘧啶、复方碘溶液、胺碘酮等,^131I治疗前进行常规检查,甲状腺最高吸^131I率测定、有效半衰期测定,甲状腺图像采集与重量测定,治疗剂量确定。^131I空腹一次口服。ATD治疗组:治疗前常规检查、治疗剂量确定。结果(1)标准化^131I治疗组痊愈率62.6%、好转率13.3%、甲减率19.5%、复发率4.6%, ATD治疗组痊愈率39.5%、好转率10.8%、甲减率3.1%、复发率46.6%,标准化^131I治疗组较ATD治疗组疗效明显提高(P〈0.05)。(2)标准化131I治疗后随着观测时间的延长,痊愈率逐渐上升,甲减发生率逐渐上升。(3)标准化^131I治疗,中青年组痊愈率高于老年组,甲减发生率低于老年组,差异均有统计学意义(P〈0.05)。结论标准化131I治疗Grave’s甲亢疗效优于ATD治疗,且较安全、经济,是一种较为理想的Grave’s甲亢治疗方法。 Objective (1)Evaluating the efficacy of Grave’s disease with ^131I comparing to antithyroid drugs(ATD). (2)Observing the efficacy of Grave’s disease in a different period after the treatment with ^131I.(3)Observing the different efficacy of Grave’s disease between old patients and the middleaged-young patients. Methods (1)We reviewed the records from patients with Graves' disease at the Affiliated Hospital of Inner Mongolia Medical University,between January 2007 and September 2010. All of the patients divided into ^131I group and ATD group.Every group consisted 195 patients. Patients in ^131I group were ranging in age from 18 to 76 years(mean 42.93±13.68),men 60,women 135,the course of Graves' disease 2.10±1.16. Patients in ATD group were ranging in age from 17 to 72 years(mean 39.67±13.92),men 65,women 130,the course of Graves' disease 1.98±1.08.(2)All patients in ^131I group stopped eating those foods(sea weed,laver,sea fish,ect)and drugs(methimazole,propylthiouracil,liquor iodi compostus,amiodarone,ect),performed these examination(radioiodine uptake,thyroid effective half-life(EHL), estimated thyroid weight before ^131I treatment,administrated ^131I dose,taked ^131I for patients,followed arrangement,and analyzed the efficacy of ^131I treatment. All patients in ATD group performed routine examinations before ATD treatment,administrat ATD dose, followed arrangement,and analyzed the efficacy of ATD treatment. Results (1)The recovery rate in ^131I group was 62.6%,the remission rate 13.3%,the hypothyroidism rate 19.5%,and the relapse rate 4.6%. The recovery rate in ATD group was 39.5%,the remission rate 10.8%,the hypothyroidism rate 3.1%,and the relapse rate 46.6%. The recovery rate and the hypothyroidism rate of patients in ^131I group were higher than of patients in ATD group(P〈0.05). The relapse rate of patients in ^131I group was significantly lower than that patients in ATD group(P〈0.05).(2)With the time of follow-up the remission rate was descending,and the recovery rate and the hypothyroidism rate were ascending after the ^131I treatment.(3)The recovery rate was lower in old group than in middleaged-young group,but the incidence of hypothyroidism was higher in old group. Conclusions ^131I can be recognized as the safer,more convenient and effective treatment than ATD for Graves' disease in patients.
出处 《浙江临床医学》 2014年第6期866-869,共4页 Zhejiang Clinical Medical Journal
基金 内蒙古自治区科技厅科技计划项目(2011MS1120)
关键词 标准化^131I治疗 ATD治疗 Grave’s甲亢 甲状腺功能减低 Radioiodine treatment Antithyroid drugs Grave' s disease Hypothyroidism
作者简介 通讯作者
  • 相关文献

参考文献12

  • 1Abraham P,Acharya S.Current and emerging treatment options for Grave' s hyperthyroidism.Ther Clin Risk Manag,2010,2(6): 29-40.
  • 2蔡敏,李险峰,陈海滨,李思进.^131Ⅰ治疗Graves病783例疗效观察及影响因素分析[J].国际放射医学核医学杂志,2008,32(2):75-78. 被引量:3
  • 3Heldey AJ,Young RE,Jones SJ,et al.Antithyroid drug in the treatment of hyperthyroidism of Graves disease: long-term follow up of 434 patients. Clin Endocrinol,1989,31(2) : 209-218.
  • 4Abraham P,AveneU A,Park CM,et al.A systematic review of drag therapy for Graves' hyperthyroidism.Eur J Endocrino,2005,153(4) : 489-498.
  • 5Peixoto MC,Coeli CM,Vaisman M.Evaluation of the medical treatment of Graves' disease(GD).Am Bras Endocrinol Metabol.2005.49(33 : 410-419.
  • 6陈再君.^(131)碘治疗甲状腺疾病的研究现状[J].临床荟萃,2004,19(4):228-229. 被引量:11
  • 7Vijayakumar V,Ali SP,Nishino T, et al. What influences early hypothyroidism after radioiodine treatment for Graves' hyperthyroidism. Clinical Nuclear Medicine,2006,31(11) : 688-689.
  • 8陈华,宋丁.^(131)I治疗Graves病甲状腺机能亢进症的5年随访研究[J].华西医学,2008,23(2):272-273. 被引量:6
  • 9Kraft O,Stepien A.Functioynal autonomies of thyroid and efficacy of radioiodine therapy.Cancer Biother Radiopharm,2007,22(2):261-267.
  • 10Allahabadia A,Daykin J,Sheppard MC,et al.Radioiodine treatment of hyperthyroidism-prognostic factors for outcome.J Clin Endocrinol Metab,2001,86(8): 3611-3617.

二级参考文献15

  • 1庞华,谭本旭,罗加.^(131)I治疗Graves病疗效影响因素分析[J].中华核医学杂志,2003,23(6):337-338. 被引量:10
  • 2耿建,陈勇,计学理,刘建国.^(131)I治疗Graves病320例疗效影响因素分析[J].山西职工医学院学报,2005,15(1):16-18. 被引量:3
  • 3唐武儒,刁丽娜,韦南仕,宋伟清,宋爱耘.^(131)I治疗225例甲亢患者的疗效分析[J].标记免疫分析与临床,2006,13(1):57-58. 被引量:2
  • 4裴著果.影像核医学[M].北京:人民卫生出版社,2000.357.
  • 5钟尚炎 莫延树 谭天秩.107例青年甲亢患者碘-131治疗远期效果观察[J].中华核医学杂志,1992,12(4):197-197.
  • 6Wartofsky L,Glinorer D,Solomon B,et al.Differences and similarities in the diagnosis and treatment of Graves' disease in Europe,Japain and the united states[J].Thyroid,1991,1(2):129-135.
  • 7Sridama V,McCormick M,Kaplan EL,et al.Long-term follow-up study of compensated low-dose 131I therapy for Graves' disease[J].N Engl J Med,1984,311(7):426-432.
  • 8Kung AW,Pun KK,Lam KS,et al.Long-term results following 131I treatment for Graves' disease in Hong Kong Chinese-discriminant factors predicting hypothyroidism[J].Q J Med,1990,76(281):961-967.
  • 9Metso S,Jaatinen P,Huhtala H,et al.Long-term follow-up study of radioiodine treatment of hyperthyroidism[J].Clin Endocrinol,2004,61(5):641-648.
  • 10Ron E,Doody MM,Becker DV,et al.Cancer mortality following for adult hyperthyroidism[J].JAMA,1998,280(4):347-355.

共引文献17

同被引文献39

  • 1金京玉,裴海成.糖尿病患者血清甲状腺激素含量变化及其相关性研究[J].中国地方病防治,2005,20(4):208-210. 被引量:7
  • 2连小兰,白耀.抗甲状腺药物的应用与评价[J].中国实用内科杂志,1996,16(12):705-706. 被引量:25
  • 3Kraft O,Stepien A.Functional autonomies of thyroid and efi cacy of radioiodine therapy[J]. Cancer Biother Radiopharm, 2007,22(2): 261-267.
  • 4Yang F, Teng W, Shan Z, et al. Epidemiological survey on the relationship between different iodine intakes and the prevalence of hyperthyroidism[J]. Eur J Endocrinol, 2002, 146(5): 613-618.
  • 5Bahn RS, Burch HB, Cooper DS, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists[J]. Endocr Pract, 2011, 17(3): 456-520.
  • 6Abraham P, Acharya S. Current and emerging treatment options for Grave's hyperthyroidism[J]. Ther Clin Risk Manag, 2010, 6: 29-40.
  • 7Teng W, Shan Z, Teng X, et al. Effect of iodine intake on thyroid diseases in China[J]. N Engl J Med, 2006, 354(26): 2783-2793.
  • 8Burch HB, Solomon BL, Cooper DS, et al. The effect of antithyroid drug pretreatment on acute changes in thyroid hormone levels after (13')I ablation for Graves' disease[J]. J Clin Endocrinol Metab, 2001, 86(7): 3016-3021.
  • 9Andrade VA, Gross JL, Maia AL. Effect of methimazole pretreatment on serum thyroid hormone levels after radioactive treatment in Graves' hyperthyroidism[J]. J Clin Endocrinol Metab, 1999, 84(11): 4012-4016.
  • 10Bahn RS, Burch HS, Cooper DS, et al. The role of propylthiouracil in the management of Graves' disease in adults: report of a meeting jointly sponsored by the American Thyroid Association and the Food and Drug Administration[J]. Thyroid, 2009, 19(7): 673-674.

引证文献5

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部